TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in bacterial diversity using Shannon Index based on 16S sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful completion of the right hemicolectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reach
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: usability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average Exogenous Basal Insulin Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average Exogenous Bolus Insulin Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average Exogenous Total Insulin Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PFS3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z-score change on Cognitive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Curative resection rates of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of spontaneous abortion
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of fetal death/stillbirth
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of pregnancy with heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Subjects With Non Herpes Manifestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the syndrome score of Qi Deficiency and Blood Stasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regeneration of alveolar bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Binocular Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With a Severe Visual Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Subjects With Ocular Serious Adverse Events Including Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to anti-retroviral therapy (ART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity or True Positive Rate (TPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False Positive Rate (FPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Pilonidal Sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Vertical force variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of non-alcoholic fatty liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean WOMAC LK3.1 Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Concentration of drug)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (concentration Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 (half time) of bicalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of mean pr-WASO
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to recurrence of Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity of Influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days of Risky Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline serum 25-OH vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of AECOPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequencies of somatic driving mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fat fraction under 0.3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of digestive and urinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Delay time change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraction time change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relaxation time change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular response to lens wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of intravitreal Macugen post injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of intravitreal VEGF 165 pre and post injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of intravitreal VEGF, TGFbeta, ET-1, PDGF, IGF-1, angiopoietin, HIF 1 alpha, HIF 1 beta pre and post injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Documented Symptomatic Atrial Fibrillation/Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in intra-abdominal adipose tissue (IAAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in pH From Baseline to <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pH From Baseline to <5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pH From Baseline to <6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAI antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in neutralization antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants with Vaccine Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Daily Blood Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: myocardial micro-damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Necroinflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Fibrosis in liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Proportion of patients maintaining a sustained response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Humphrey visual field sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of THRIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of PACER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression profiling of skeletal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Budget impact of discontinuing TKI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: difference in IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: change in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes from Baseline in Mini-Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes from Baseline in Blessed-Roth Behavior Scale (BBS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from Baseline in Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Meningococcal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neural effects- Blood Oxygenation Level Dependent (BOLD) images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision scores of the ROP-HC classifier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to depot injection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Confirmed HBV and HCV test uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean pain level during the active phase of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment expectancy and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention (% of drop-outs)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence rate of foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of venous bubbles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analysis of blood-borne tumor biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of MCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of MCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methadone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Immune Marker Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery Room Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Not Meeting Criteria for Death or Hospitalization on Invasive Mechanical Ventilation or ECMO
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic performance of 68Ga-PSMA imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response after locoregional therapy in HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between PSMA uptake and tissue PSMA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Day of Initial Vaginal Bleeding Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Prevalence of ankyloglossia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Number of Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global Health Status (Quality of Life evolution)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease free overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Major haemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: Auditory abnormalities assessed by ABR wave form latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hoffman Auditory Hallucination Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GIP area under the curve after OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correlation of PC20 FEV1 and PD20 FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in upper extremity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Internal Lymphedema at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Change from Baseline External Lymphedema at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Change from Baseline Staging Lymphedema at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Change from Baseline Characteristics of Tissue Changes (edema and/or fibrosis) at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline 3D Surface Scanning and Volume Evaluation at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of calcium, phosphorus, and intact parathyroid hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical indicators of nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Enhanced coagulation state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of buccal micronuclei
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean tau deposition in different region of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean tau intensity in different region of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: correlation with cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Differences in gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in plasma concentrations of drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in treadmill exercise tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased incidence of rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Post-partum perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of live-born children with a delivery at term and a normal cardiac rhythm
Endpoint domain: Mortality/survival
Primary endpoint: Change of systolic blood pressure baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of heart beat rate baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change From Baseline in Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Increase in Glutathione (GSH) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC) for glucose and insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular death or unscheduled hospitalizations due to cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Change in brown adipose tissue (BAT) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in counter-movement jump (CMJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 15-meter sprint run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in viscoelastic properties of the Achilles tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PrEP Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP Persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Solid tumor biological insights
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neonatal intracranial hemorrhage or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of [18F]NAV4694 Brain PET scan positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compositional changes of the oral and gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Development of malaria parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: excessive daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Drug half-life in plasma (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of Oral Intake of Energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequacy of Oral Intake of Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of vinflunine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change in Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Who Achieved Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete secretory activity on endometrial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of brominated flame retardant (BFR) in adipose tissue and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Post Infectious Irritable Bowel Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Voriconazole Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NASH resolution on liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ≥ 1 stage fibrosis improvement on liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: [11C]5-hydroxy-tryptophan uptake in the pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Range of movement of the operated knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Additional procedures/interventions to gain motion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concordance/disordance estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in hypertension knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in patient engagement in self management activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning